Edwards Lifesciences Corporation $EW Holdings Raised by Czech National Bank

Key Points

• The **Czech National Bank** increased its stake in **Edwards Lifesciences Corporation** by **5.8%**, owning **143,385 shares** valued at approximately **$11.2 million** as of the most recent quarter.
• Brokerages have raised target prices on Edwards Lifesciences, with estimates now ranging from **$80.00 to $95.00**, indicating strong market confidence in the stock.

Czech National Bank grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,385 shares of the medical research company's stock after buying an additional 7,917 shares during the period. Czech National Bank's holdings in Edwards Lifesciences were worth $11,214,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its position in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd acquired a new position in Edwards Lifesciences in the 2nd quarter worth $1,760,000. Dynamic Advisor Solutions LLC lifted its holdings in Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after buying an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares in the last quarter. Finally, United Asset Strategies Inc. lifted its holdings in Edwards Lifesciences by 10.4% in the 1st quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock worth $13,450,000 after buying an additional 17,412 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.16 on Friday, hitting $74.39. The stock had a trading volume of 8,177,895 shares, compared to its average volume of 4,492,477. The company's 50-day moving average is $78.76 and its two-hundred day moving average is $75.49. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $43.67 billion, a price-to-earnings ratio of 10.70, a P/E/G ratio of 3.63 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup reiterated a "buy" rating and issued a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Evercore ISI boosted their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 13th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $87.17.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.